Development programme
RECONNECT — bremelanotide (PT-141)
The pivotal programme for the melanocortin receptor agonist bremelanotide in hypoactive sexual desire disorder in premenopausal women.
The pivotal programme for the melanocortin receptor agonist bremelanotide in hypoactive sexual desire disorder in premenopausal women.
Sponsor class: Manufacturer-sponsored. First record: 2014.
Showing 0 records on this page
Records in this programme
11 documents
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| RECONNECT-301 | PT-141 (bremelanotide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 626 | 2019 | Moderate |
| RECONNECT-302 | PT-141 (bremelanotide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 630 | 2019 | Moderate |
| RECONNECT-301-ADHERENCEprogramme record | PT-141 (bremelanotide) | Phase 3 | Reported | Observational | — | 2019 | Very low |
| RECONNECT-301-BODY-COMPprogramme record | PT-141 (bremelanotide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| RECONNECT-301-QOLprogramme record | PT-141 (bremelanotide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| RECONNECT-301-REGIONAL-CNprogramme record | PT-141 (bremelanotide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| RECONNECT-301-REGIONAL-JPprogramme record | PT-141 (bremelanotide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| RECONNECT-302-DDIprogramme record | PT-141 (bremelanotide) | Phase 1 | Reported | Randomised crossover | — | 2019 | Very low |
| RECONNECT-302-HEPATIC-IMPprogramme record | PT-141 (bremelanotide) | Phase 1 | Reported | Phase 1 ascending dose | — | 2019 | Very low |
| RECONNECT-302-PKprogramme record | PT-141 (bremelanotide) | Phase 1 | Reported | Phase 1 ascending dose | — | 2019 | Very low |
| RECONNECT-302-RENAL-IMPprogramme record | PT-141 (bremelanotide) | Phase 1 | Reported | Phase 1 ascending dose | — | 2019 | Very low |